Profile data is unavailable for this security.
About the company
EKF Diagnostics Holdings plc is a diagnostics and biotechnology company specializing in the manufacturing and distribution of advanced medical technologies and patient-focused solutions. The Company develops and produces in-vitro diagnostic (IVD) devices and tests designed for use at or near the patient’s location. It provides a suite of products for diabetes management, including glucose monitoring systems and associated consumables. It offers devices, supplies, and consumables for measuring hemoglobin levels, including tools for detecting hemoglobin variants. It also develops and supplies diagnostic and therapeutic enzymes, proteins, reagents, and biomaterials. It provides precision fermentation, custom bioprocessing, and contract manufacturing services for pharmaceuticals and other biological products. It supplies beta-hydroxybutyrate (HB) products used in ketone detection to support the diagnosis of diabetic ketoacidosis and other clinical conditions.
- Revenue in GBP (TTM)50.22m
- Net income in GBP6.12m
- Incorporated2002
- Employees297.00
- LocationEKF Diagnostics Holdings PLCAvon HSE, 19 Stanwell RoadPENARTH CF64 2EZUnited KingdomGBR
- Phone+44 29 2071 0570Fax+44 29 2070 5715
- Websitehttps://www.ekfdiagnostics.com/
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Aptamer Group PLC | 1.20m | -2.42m |
| Renalytix PLC | 2.20m | -14.99m |
| Aoti Inc | 46.93m | 1.73m |
| Ondine Biomedical Inc | 1.18m | -12.84m |
| Inspecs Group PLC | 192.83m | -3.31m |
| Creo Medical Group PLC | 2.20m | 12.60m |
| SDI Group PLC | 69.29m | 4.59m |
| EKF Diagnostics Holdings PLC | 50.22m | 6.12m |
| Tristel Plc | 46.46m | 6.64m |
| Advanced Medical Solutions Group plc | 220.30m | 9.12m |
Institutional shareholders
| Holder | Shares | % Held |
|---|---|---|
| Harwood Capital LLPas of 20 Oct 2025 | 131.38m | 30.22% |
| Gresham House Asset Management Ltd. (Investment Management)as of 24 Mar 2025 | 51.14m | 11.76% |
| Liontrust Investment Partners LLPas of 18 Sep 2025 | 48.57m | 11.17% |
| Schroder Investment Management Ltd.as of 16 Jun 2025 | 27.25m | 6.27% |
| Ruffer LLPas of 24 Mar 2025 | 22.78m | 5.24% |
| Castlefield Investment Partners LLPas of 31 Jul 2025 | 3.72m | 0.86% |
| Octopus Investments Ltd.as of 01 Dec 2025 | 3.63m | 0.84% |
| AXA Investment Managers UK Ltd.as of 01 Dec 2025 | 3.37m | 0.78% |
| Canaccord Genuity Wealth Ltd.as of 30 Sep 2025 | 3.00m | 0.69% |
| Hargreaves Lansdown Fund Managers Ltd.as of 01 Dec 2025 | 2.81m | 0.65% |
